Advestra advises on the IPO of BioVersys

BioVer­sys, a lead­ing Swiss biotech com­pany spe­cial­iz­ing in nov­el anti­bac­teri­al products for ser­i­ous life-threat­en­ing infec­tions, suc­cess­fully com­pleted its ini­tial pub­lic offer­ing on SIX Swiss Exchange. The IPO con­sisted of a primary offer­ing involving a cap­it­al increase, which gen­er­ated gross pro­ceeds in the amount of approx­im­ately CHF 80 mil­lion. Trad­ing in the shares star­ted on 7 Feb­ru­ary 2025.

Cit­ig­roup, UBS and Sti­fel Europe acted as joint glob­al coordin­at­ors and Octavi­an and Mira­baud as selling agents in this transaction.

Advestra acted as leg­al coun­sel to Cit­ig­roup, UBS and Sti­fel Europe. The team included Annette Weber, Sandro Fehl­mann, Valérie Bayard and Luca Schmid (all Cap­it­al Mar­kets) as well as Céline Mar­tin (Tax).